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Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most
malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and
radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report
several determinants of resistance to this aggressive therapy: (1) O6-methylguanine-DNA methyltransferase (MGMT), (2) the
complexityofseveralalteredsignalingpathwaysinGBM,(3)theexistenceofgliomastem-likecells(GSCs),and(4)theblood-brain
barrier. Many studies aim to overcome these determinants of resistance to conventional therapy by using various approaches to
improve the dismal prognosis of GBM such as modifying TMZ administration and combining TMZ with other agents, developing
novel molecular-targeting agents, and novel strategies targeting GSCs. In this paper, we review up-to-date clinical trials of GBM
treatments in order to overcome these 4 hurdles and to aim at more therapeutical eﬀect than conventional therapies that are
ongoing or are about to launch in clinical settings and discuss future perspectives.
1.Introduction
Glioblastoma multiforme (GBM) is one of the most fre-
quently occurring tumors in the central nervous system and
the most malignant tumor among gliomas. A subanalysis in
aninternationalrandomizedtrialbytheEuropeanOrganiza-
tion for Research and Treatment of Cancer/National Cancer
Institute of Canada (EORTC/NCIC) compared the results of
radiotherapy (RT) alone with those of concomitant RT and
temozolomide(TMZ)andfoundthattheadditionofTMZto
radiotherapy for newly diagnosed GBM resulted signiﬁcant
survival beneﬁt [1], additionally the subgroup analysis of the
5-year survival data of the EORTC/NCIC trial also revealed
its beneﬁt [2]. Since then, TMZ has been the current ﬁrst-
line chemotherapeutic agent for GBM. However, despite
aggressive treatment including surgery, adjuvant TMZ-based
chemotherapy, and RT, GBM still has a dismal prognosis:
the median survival is 14.6 months from diagnosis. Many
studies aim to overcome several determinants of resistance
to conventional therapy by using various approaches to
improve the dismal prognosis of GBM such as modifying
TMZadministrationandcombiningTMZwithotheragents,
developing novel molecular-targeting agents, and novel
strategies targeting GSCs. In this paper, we review up-to-
date clinical trials of GBM treatments in order to overcome
determinants and to aim at more therapeutical eﬀect than
conventional therapy that are ongoing or are about to launch
in clinical settings and discuss future perspectives.
2. Overcoming Alkylating Agent Resistance due
to MGMT
MGMT is capable of counteracting the cytotoxicity induced
by O6-alkylating agents. Furthermore, increased MGMT
expression is well correlated with in vitro and in vivo glioma
resistance to TMZ [3–6]. However, in this process, MGMT
is rapidly degraded via the ubiquitin-proteasome pathway
after receiving alkyl groups from DNA; the repletion of
cellular MGMT pools also depends on the resynthesis of
the molecule [7]. This makes MGMT a suitable target for
intervention to improve the therapeutic eﬃcacy of TMZ.2 Neurology Research International
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Figure 1: RTOG 0525/EORTC 26052-22053 (dose-dense) study. The study aimed to determine if intensiﬁed TMZ (75–100mg/m2 × 21
days, q4weeks) improves overall survival or progression-free survival compared to the standard arm (150–200mg/m2 × 5 days, q4weeks).
Additional treatment options are limited in cases of re-
lapse after a standard-dose TMZ treatment (150–200mg/
m2× 5 days, q4weeks). Supported by the assumption
that continuous treatment with alkylating agents induces
the depletion and exhaustion of MGMT activity, many
researchershaveinvestigatedtheeﬀectsofdiﬀerentdose-and
time-modiﬁed TMZ schedules.
2.1. RTOG 0525/EORTC 26052-22053 (Dose-Dense) Study.
This is a randomized phase III trial comparing standard
adjuvant TMZ with a dose-dense schedule in newly diag-
nosed GBM [8]. This trial was based on a report indicating
that dose-dense TMZ prolongs MGMT depletion in blood
mononuclear cells and possibly tumors; the study aimed
to determine if intensiﬁed TMZ (75–100mg/m2× 21 days,
q4weeks) improves overall survival (OS) or progression-
free survival (PFS) compared to the standard arm (150–
200mg/m2× 5 days, 4weeks) after the standard concomitant
RT+TMZ (Figure 1). No signiﬁcant diﬀerence was observed
between the standard and experimental arms with respect to
median OS (16.6 versus 14.9 months, P = 0.63), median
PFS (5.5 versus 6.7 months, P = 0.06), or MGMT methy-
lation status. In addition, the experimental arm signiﬁcantly
increased grade ≥3 toxicity including lymphopenia and
fatigue. This study did not demonstrate improved eﬃcacy
of dose-dense TMZ for newly diagnosed GBM regardless of
MGMT methylation.
2.2. Continuous Dose-Intense TMZ in Recurrent Malignant
Glioma: The RESCUE Study. There is no consensus on
the optimal approach for patients with recurrent GBM,
in which recurrence occurs after TMZ is initially used
followedby12ormorecyclesofadjuvanttherapy.Protracted
drug exposure may reduce MGMT activity as described
above. In addition, protracted TMZ dosing may inhibit
endothelial cell recovery in the tumor and the activity
of circulating endothelial precursors as well as upregulate
thrombospondin-1, leading to an antiangiogenic eﬀect [9–
12]. Ninety-one patients with GBM were prospectively
divided into 3 groups according to the timing of progression
during adjuvant therapy: early, extended, and rechallenge
[13] (Figure 2). All patients received 50mg/m2/day TMZ on
a continuous (28/28) basis for a maximum of 12 months
or until progression occurred. The primary endpoint of this
study was 6 months PFS (PFS6). PFS6 was 27.3%, 7.4%,
and 35.7% in the early, extended, and rechallenge groups,
respectively; 1-year survival from time of study entry was
27.3%, 14.8%, and 28.6% for the 3 groups, respectively.
The results of the RESCUE study suggest that patients who
progress early compared with those who progress late or
after a treatment-free interval may respond diﬀerently to the
continuous dose-intense TMZ re-treatment. However, given
that no consensus treatment option exists for patients with
r e c u r r e n tG B M ,i tw o u l db eo fn o t et h a tc o n t i n u o u sd o s e -
intense TMZ serves as a useful platform for combination
strategies.
2.3.One-Week-on/One-Week-oﬀTMZinElderlyPatientswith
Newly Diagnosed Malignant Gliomas: The NOA-08 Study.
Both surgery and radiation therapy are less tolerated in
elderly patients than in younger ones. To reevaluate the
widespread therapeutic nihilism with malignant glioma in
the elderly (age >65), the Neurooncology Working Group
(NOA) of the German Cancer Society conducted a ran-
domized phase III trial to compare a 1-week-on/1-week-
oﬀ TMZ schedule at 100mg/m2 with dose modiﬁcation in
25mg steps in both directions and involved ﬁeld RT (54–
60Gy) in elderly patients with newly diagnosed anaplastic
astrocytoma or GBM (NOA-08) [14]. The primary endpoint
was the median OS during follow-up in the 12 months after
the operation. Patient characteristics were balanced between
arms in the intention-to-treat population (n = 373) except
for more resections and more anaplastic astrocytomas in
the RT arm. TMZ was not demonstrated to be superior.
However, patients in the TMZ arm had an increased risk
of death (HR = 1.24 [95% CI: 0.94–1.63]) compared with
those in the RT arm. The rates of adverse and serious adverse
events were also higher in the TMZ arm. This trial failedNeurology Research International 3
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Figure 2: Continuous dose-intense TMZ in recurrent malignant glioma: the RESCUE study. Ninety-one patients with GBM were
prospectively divided into 3 groups according to the timing of progression during adjuvant therapy: early, extended, and rechallenge.
to demonstrate the noninferiority of dose-intensiﬁed TMZ
alone compared with RT alone in the primary treatment
of older patients with malignant gliomas. Whether RT plus
TMZ is superior to RT alone, is being addressed in an
ongoing companion trial conducted by the NCIC, EORTC,
and RTOG.
2.4. Combination with 1,3-Bis (2-Chloroethyl)-1-Nitrosourea:
The TEMOBIC Study. Although TMZ replaced nitrosoureas
such as 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) as the
standard initial chemotherapy in the treatment of GBM, the
DNA damage induced by nitrosoureas and TMZ is partially
repaired by MGMT. Thus, combined administration of
nitrosoureas and TMZ might overcome MGMT-mediated
resistance via MGMT depletion, yielding superior treatment
results compared with the administration of TMZ alone. A
phase II study was conducted in newly diagnosed anaplastic
oligodendrogliomas[15].Thisstudyassessedtheeﬃcacyand
safety of BCNU (150mg/m2, day 1) and TMZ (110mg/m2,
days1–5)every6weeksforupto6cyclesbeforeconventional
RT (60Gy/30 fr) in 54 patients. Grade 3-4 toxicities included
thrombopenia (n = 20), neutropenia (n = 13), and elevated
transaminases (n = 5). Treatment was discontinued in 4
patients, and possible treatment-related deaths occurred in
3 patients. The combination should be carefully considered
due to its signiﬁcant toxicity.
2.5.CombinationwithO6-Benzylguanine. O6-benzylguanine
(O6-BG) is a potent inhibitor that irreversibly inactivates
MGMT by covalently transferring its benzyl group to the
cysteine residues of MGMT’s active site [16]. As a result, O6-
BG enhances TMZ cytotoxicity in MGMT-proﬁcient glioma
cells both in vitro and in vivo but not in MGMT-deﬁcient
cells [17]. Since patients with MGMT overexpression in
tumors respond more poorly to alkylating agents, co-
administration of O6-BG to deplete the tumor pools of
MGMT to enhance drug cytotoxicity has been previously
attempted in a clinical setting [18, 19]. However, systemic
delivery of O6-BG increased the myelotoxicity caused by
MGMT depletion in bone marrow cells. Therefore, the dose
of alkylating agents was reduced to a subtherapeutic level.
Consequently, none of the patients responded to this drug
combination. Therefore, the therapeutic potential of adding
O6-BG to enhance TMZ cytotoxicity in tumor cells has been
discouraging thus far.
2.6. Combination with Cilengitide: The CORE Study. Cilen-
gitide, a selective αvβ3/5 integrin inhibitor, exhibits dose-
dependent antitumor activity in patients with recurrent
GBM [20]. A randomized controlled phase II trial (CORE)
was designed as stepwise cilengitide intensiﬁcation in sub-
jects with newly diagnosed GBM and unmethylated MGMT
promoter status [21]. The toxicity from this treatment was
minimal. A further phase trial testing the use of inten-
siﬁed cilengitide (2000mg, 5 days/week) in combination
with concomitant RT with TMZ is now recruiting patients
with newly diagnosed GBM with unmethylated MGMT
status.
2.7. Combination with Interferon-β: The JCOG0911 (INTE-
GRA)Study. Interferon(IFN)-β exertspleiotropicbiological
eﬀects and is widely used either individually or in combina-
tion with other antitumor agents to treat malignant gliomas
and melanomas [22]. In the treatment of malignant gliomas,
IFN-β can act as a drug sensitizer by enhancing the toxicity
of chemotherapeutic agents against various neoplasms when
administered in combination with nitrosoureas. Combina-
tion therapy with IFN-β and nitrosoureas is primarily used4 Neurology Research International
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Figure 3: Combination with interferon-β: the JCOG0911 (INTEGRA) study. A randomized phase II clinical trial in patients with newly
diagnosed GBM is under way to compare the standard-of-care regimen with the addition of IFN-β in the upfront settings.
for the treatment of gliomas in Japan [23]. In a previous
in vitro study in human glioma cells, we found that IFN-
β markedly enhances chemosensitivity to TMZ [24]; this
ﬁnding suggests that one of the major mechanisms by which
IFN-β enhances chemosensitivity is the downregulation of
MGMT transcription via p53 induction. This eﬀect was also
observed in an experimental animal model [25]. The results
of these 2 studies suggest that compared with chemother-
apy with TMZ alone and concomitant RT, chemotherapy
with IFN-β and TMZ with concomitant RT might further
improve the clinical outcomes of malignant gliomas. To
evaluate the safety, feasibility, and clinical eﬀectiveness of
combination therapy with IFN-β and TMZ, a phase I clinical
study, the Integrated Japanese Multicenter Clinical Trial:
a Phase I Study of Interferon-β and TMZ for Glioma in
Combination with RT (INTEGRA study), was conducted.
The primary endpoint was the incidence of adverse events.
The exploratory endpoints were PFS and OS. The study
population comprised 16 patients with newly diagnosed
gliomas and 7 with recurrent high-grade gliomas. Grade 3-
4 leukocytopenia and neutropenia were observed in 6.7%
and 13.3% of the patients, respectively. Overall, 40% of
the patients exhibited an objective response to therapy. In
patients with newly diagnosed GBM, the median OS time
was 17.1 months and the rate of 1-year PFS was 50%.
This regimen is safe and well tolerated by the patients,
and may prolong the survival of patients with GBM. A
randomized phase II clinical trial in patients with newly
diagnosed GBM is under way to compare the standard-of-
care regimen with the addition of IFN-β in the upfront
settings (Figure 3).
3.StrategiesTargetingtheAlteredSignaling
Pathways(Figure4)
3.1. VEGF Signaling. GBM is characterized by sustained
angiogenesis—the key regulator of which is vascular endo-
thelial growth factor (VEGF). Bevacizumab (Avastin, BEV)
is a humanized monoclonal antibody that binds to and
inhibits the activity of VEGF [26–29]. In preclinical models,
BEV has been shown to exhibit activity against GBM both
alone and in combination with RT and TMZ. The beneﬁt
and safety proﬁle of BEV was conﬁrmed in a randomized,
noncomparative phase II trial (BRAIN study; AVF3708g) in
GBM patients who experienced ﬁrst or second recurrence
following standard-of-care with TMZ [27]. In both the BEV
(n = 85) and BEV plus irinotecan (n = 82) cohorts,
objective response rate and PFS6 were signiﬁcantly higher
than those of the external historical controls. It might
be important to state that the addition of irinotecan to
bevacizumab did not improve outcome, and PFS6 as a
primary endpoint is a controversial particularly in patients
treated with antiangiogenic therapies (such as bevacizumab)
that can lead to improved imaging ﬁndings without actual
tumor response (a so-called pseudoresponse). In any case, in
light of these results, studies were initiated to evaluate BEV
in combination with RT plus TMZ as the upfront treatment
for newly diagnosed GBM. In a noncomparative study in 70
newly diagnosed GBM patients, BEV in combination with
RT plus TMZ resulted in median OS and PFS times of 19.6
and 13.6 months, respectively. In another nonrandomized
p h a s eI Is t u d y[ 30], the eﬀects of RT plus TMZ were
compared with (n = 25) and without (n = 31) BEV;Neurology Research International 5
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Figure 4: Altered signaling pathways and inhibitors. Receptor tyrosine kinase (RTK), EGFR and platelet-derived growth factor receptor
(PDGFR) are receptor tyrosine kinases (RTKs). In GBM, 40–60% of cases exhibit EGFR ampliﬁcation and high EGFR protein expression
levels. PDGFR is overexpressed at the transcriptional level. EGFR activation initiates signal transduction such as the PI3K/Akt pathway.
EGFR variant III (EGFRvIII) is a constitutively activated mutation of EGFR, that is, expressed in approximately 25% of GBM cases but not in
normal tissues; Sonic Hedgehog (SHH), SHH is a secreted protein critical for pattern formation in the central nervous system. SHH ligand
bindingtoitsreceptors,patchedhomolog(PTCH)andsmoothenedhomolog(SMO),leadstotheactivationofgliotactin(GLI)transcription
factors that are translocated into the nuclease to regulate various cellular activities, including the maintenance of cell stemness, survival, and
proliferation; NOTCH, The Notch pathway is initiated by the binding of transmembrane ligands on one cell to the notch receptors on an
adjacent cell. This binding causes the γ-secretase-mediated proteolytic release of the Notch intracellular domain (NICD). Released NICD
translocates into the nucleus and then turns CSL (a transcriptional factor) from a repressor to an activator, causing various eﬀects; WNT,
Wnt signals are divided into 2 diﬀerent pathways: the canonical or WNT/β-catenin pathway is involved in cell fate determination and the
noncanonicalpathwayisinvolvedinthecontrolofcellmovementandtissuepolarity[35].FollowingthebindingofWntproteintoareceptor
complex comprising Frizzleds/low-density lipoprotein receptor-related protein (Fz/LRP), cytoplasmic disheveled (Dvl) is phosphorylated.
The phosphorylation of Dvl inhibits the activity of glycogen synthase kinase-3β (GSK-3β), elevating nonphosphorylated β-catenin levels in
thecytoplasm.β-CatenintranslocatesintothenucleusandformsacomplexwithmembersoftheT-celltranscriptionfactor(TCF)/lymphoid
enhancer-binding factor (LEF) family of transcription factors.
RT plus TMZ with BEV resulted in increased PFS6 (87%
versus 52%), median PFS (12 versus 7 months, P = 0.0001),
2-year OS rate (50% versus 22%), and median OS (24.0
versus 17.5 months, P = 0.09). A large randomized double-
blind placebo-controlled phase III trial (AVAglio, BO21990,
NCT00943826) is currently recruiting approximately 920
newly diagnosed GBM patients from 140 centers worldwide
[31]. However, there is evidence suggesting that anti-VEGF
treatment increases tumor cell invasion in GBM [32].
While BEV strongly decreases contrast enhancement, this is
accompanied by a 68% increase in inﬁltrating tumor cells
in the brain parenchyma. These data strongly suggest that
vascular remodeling induced by anti-VEGF treatment leads
to a more hypoxic tumor microenvironment. This favors a
metabolic change in the tumor cells toward glycolysis, which
leads to tumor cell invasion into normal brain tissue.
Cediranib is another potent oral VEGF signaling in-
hibitor that exhibits activity against all 3 VEGF receptors
[33]. REGAL (NCT00777153) is a randomized phase III
study comparing cediranib and lomustine (CCNU) in
patients with recurrent GBM. Between October 2008 and
September 2009, 325 patients from 10 countries were en-
rolled. The ﬁrst clinical results of the REGAL trial were
negative [34]. Other clinical trials are under way to assess
cediranib either as a monotherapy or in combination with
other agents.6 Neurology Research International
3.2. EGFR and PDGF Signaling. To date, various genetic
alterations are reported in GBMs such as epidermal growth
factor receptor (EGFR) ampliﬁcation, CDKN2A loss, phos-
phatase and tensin homolog (PTEN) loss, and so forth.
Among these various alterations, several alterations deregu-
late pathways involving the RTK/PI3K/Akt/mTOR pathway
[36, 37], which is regarded as the most amenable pathway
to pharmacologic intervention [38]. This pathway contains
a number of key kinase intermediates as shown below.
EGFR and platelet-derived growth factor receptor (PDGFR)
are receptor tyrosine kinases (RTKs). In GBM, 40–60%
of cases exhibit EGFR ampliﬁcation and high EGFR pro-
tein expression levels [39, 40]. PDGFR is overexpressed
at the transcriptional level. This EGFR activation initiates
signal transduction such as the PI3K/Akt pathway. The
phosphatidylinositol-3  kinases (PI3Ks) are lipid kinases
that are activated downstream of growth factor receptor
signaling. Activated PI3Ks phosphorylate the lipid phos-
phatidylinositol(4,5)-bisphosphate(PIP2)togeneratephos-
phatidylinositol (3, 4, 5)-triphosphate (PIP3). PIP3 recruits
Akt, which is the major eﬀector of this pathway, to the cell
membrane. Activated Akt enhances cell growth, survival,
and proliferation and indirectly enhances the activity of
mammalian target of rapamycin (mTOR), which controls
cell growth by regulating various cellular processes. PTEN
suppresses Akt phosphorylation by reversing PI3K-driven
phosphorylation, resulting in the inhibition of the PIP3
signal thus suppressing cell proliferation [36, 41, 42]. Con-
sidering that these various alterations aﬀect cell survival and
proliferation, many studies suggest a novel strategy targeting
these small molecules to improve the dismal prognosis of
GBM [43].
To date, the small-molecule inhibitors of EGFR that were
introduced in clinical trial include geﬁtinib, erlotinib, and
nimotuzumab [44–46]. Geﬁtinib is an oral low-molecular-
weight adenosine triphosphate mimetic of the anilinoquina-
zoline family. Geﬁtinib is an eﬃcient therapeutic agent
for a subset of patients with nonsmall-cell lung cancers
(NSCLC), particularly the ones who harbor an activating
EGFR mutation. However, several clinical trials evaluating
the eﬃcacy of geﬁtinib with or without TMZ in GBM
report disappointing eﬃcacy. Uhm et al. report that patients
who exhibit adverse reactions to geﬁtinib (e.g., rash and
diarrhea) have prolonged overall survival [47] Erlotinib is
also an EGFR tyrosine kinase inhibitor (EGFR-TKI). This
EGFR-TKI exhibits clinical activity particularly in tumors
that have mutations in the adenosine triphosphate binding
pocket of the tyrosine kinase domain of the EGFR gene.
Although several clinical trials have evaluated the eﬃciency
of erlotinib, almost all failed to demonstrate its eﬃciency or
any additional beneﬁt [45, 48]. Nimotuzumab was tested in
an open-label randomized phase III trial in 150 patients with
newly diagnosed GBM, but the interim analysis has failed to
demonstrate eﬃcacy [49]. EGFR variant III (EGFRvIII) is a
constitutively activated mutation of EGFR that is expressed
in approximately 25% of GBM cases but not in normal
tissues. PF-04948568 is a vaccine containing a 13-amino acid
sequence unique to EGFRvIII. A randomized phase IIb/III
ACTIII study was initiated; the primary objective was to
reject the null hypothesis that less than 53% of patients
will be progression-free at 5.5 months from ﬁrst vaccination
[50]. Since this vaccination was well tolerated and the
null hypothesis was rejected, further study is warranted.
Afatinib, an irreversible erbB family blocker, exhibits high
in vitro activity in tumor cell lines resistant to reversible
EGFR inhibitors. This study compared the afatinib alone
and afatinib with TMZ therapies with TMZ alone therapy
[51]. The results show that afatinib alone is less eﬀective than
TMZ alone. Furthermore, afatinib with TMZ is comparable
to TMZ alone.
Another TKI activating the PI3K/Akt/mTOR pathway is
PDGFR. Imatinib blocks the ATP-binding site of tyrosine
kinase proteins including PDGFR and inhibits the activity
of PDGFR. The clinical eﬃciency of imatinib against other
cancers such as chronic myeloid leukemia (CML) and gas-
trointestinal stromal tumors (GISTs) has been demonstrated
[52–54]. In addition, since imatinib is active in GBM cell
lines and mouse models, several clinical trials have evaluated
its eﬃciency in GBM patients [43, 55, 56]. However, most
of these clinical trials were not able to demonstrate any
advantage of imatinib. It should be noted that most of
these clinical trials to date enrolled unselected patients in
whom the relative importance of each dysregulated molecule
aﬀecting tumor growth was largely unknown, which may be
why these clinical trials demonstrate no advantage. Sunitinib
is an orally available multitarget TKI of FDR, PDGFR, and
c-kit. It exhibits broad-spectrum antiangiogenic activity.
A phase II trial with stratiﬁcation of prior use of BEV
was designed for recurrent GBM to assess the safety and
eﬃcacy of 37.5mg sunitinib administered on a continuous
daily schedule. Twenty-eight and twenty-one patients have
been enrolled in the BEV-resistant and BEV-na¨ ıve arms,
respectively [57]. However, no patient has reached PFS6 at
all. The eﬃcacy of dasatinib, a PDGF and Src inhibitor,
was evaluated retrospectively in recurrent malignant gliomas
[58]. Twenty patients were treated with dasatinib alone, and
in combinations with BEV and other anticancer drugs, or
BEV-na¨ ıve. Dasatinib alone or in combination with BEV
did not exhibit activity because low central nervous system
penetration may limit its activity.
3.3. Targeting the PI3K/Akt/mTOR Pathway. Following the
activation of RTK, the activated PI3K/Akt/mTOR pathway
induces cell growth and proliferation. In addition to the
RTK inhibitors described above, several studies suggest
potential therapeutic targets of PI3K, Akt, and mTOR [38,
59, 60]. A preclinical study demonstrated that LY294002
and wortmannin inhibit PI3K. Because of toxic eﬀects, poor
pharmaceuticalproperties,andalackofselectivity,theuseof
these agents was restricted in the preclinical study. Recently,
the thienopyrimidine drug GDC-0941 was found to exhibit
excellent oral anticancer activity in a preclinical study and
is now undergoing a phase I clinical trial in cancer patients
[59]. In addition, imidazopyridines, pyridopyrimidines,
quinazolyne derivatives, thiazoles, azolepyrimidine deriva-
tives, and other chemotypes are reported to inhibit the PI3K.
Akt is also heavily targeted for therapy. The phospholipid
perifosine is suggested to interfere with the association ofNeurology Research International 7
the Akt PH domain with PIP3, thus blocking the membrane
localizationoftheprotein.Perifosineiscurrentlyundergoing
phase II clinical trials for prostate, head and neck, breast,
and pancreatic cancers, melanomas, and sarcomas [61]. The
mTOR kinase is intimately linked to PI3K/Akt signaling
as well as the regulation of protein synthesis, cell growth,
and survival. The dysregulation of mTOR is regarded as a
therapeutic target. In addition, rapamycin and its analogs
inhibit mTOR kinase via a rather indirect fashion. At
present, 2 rapamycin analogs, temsirolimus and everolimus,
are approved for the treatment of metastatic renal cell
cancer [62]. Several clinical trials evaluating the eﬃciency
of mTOR inhibitors such as temsirolimus in gliomas have
been performed. The results of these trials suggest that
monotherapy with temsirolimus does not prolong survival
but combination therapy enhances its eﬃciency [43].
3.4. Glutamate Pathway. Glutamate is a major excitatory ne-
urotransmitter in CNS. It is stored in synaptic vesicles and
released as neurotransmitter. After it serves as neurotrans-
mitter, it is rapidly took up at the plasma membrane of
neurons, glial cells, and terminated. Glioma cells released
glutamate in concentration, and glutamate reuptake is
reduced due to reduction of glutamate transporter. This
increased glutamate inﬂuences the surrounding cells and
the glutamatergic system is associated with the prolif-
eration, survival and migration of gliomas. Talampanel
is an antagonist of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptor. The
phase 2 trial of Talampanel combined with conventional
TMZ and radiation for 72 newly diagnosed GBM patients
showed median survival time of 18.3 months. This trial
suggested the eﬃciency of Talampanel [63]. The other phase
2 trial evaluated the eﬃciency of Talampanel as single agent
for recurrent malignant glioma patients. This trial shows no
signiﬁcant activity as single agent (median OS; 13 weeks)
[64].
3.5. Histone Deacetylase. Vorinostat is an oral histone de-
acetylase (HDAC) inhibitor. HDAC acts on nucleosomal
histones, leading to the tight coiling of chromatin and
silencing of the expression of various genes. HDAC regulates
c e l ls u r v i v a l ,p r o l i f e r a t i o n ,t u m o rc e l ld i ﬀerentiation, cell
cycle arrest, and apoptosis. There is preclinical evidence that
vorinostat has antitumor activity against malignant glioma
cell lines in vitro and orthotopic xenografts in vivo. Animal
experiments also support the conclusion that vorinostat
crosses the blood-brain barrier [65]. On the basis of these
results, a phase I study of vorinostat in combination with
TMZ was performed and revealed that this treatment is well
tolerated; a phase II trial is under way [66].
4.Strategy TargetingGlioma-InitiatingCells
Several studies revealed that gliomas harbor a small popula-
tion of cells termed glioma stem-like cells (GSCs) [67, 68].
GSCs have the ability to undergo self-renewal and initiate
tumorigenesis. GBM forms extensively heterogeneous bulk
tumors; this heterogeneity may be crucial for treating this
disease. The presence of GSCs may be an important clue
in clarifying the details of this heterogeneity. In addition,
GSCs are resistant to a wide variety of chemotherapeutic
agents and possess a remarkable ability to recover from
cytotoxic therapy [69]. Furthermore, GSCs play a crucial
role in RT failure, as tumors surviving RT are enriched in
GSCs. Therefore, an alternative strategy involving selective
targeting of this functionally distinct chemo- and radiation-
resistant small group of GSCs rather than the bulk of
the tumor may be more successful in treating this deadly
disease [70]. GSCs exhibit various alterations to signaling
pathway activity including PTEN, sonic hedgehog (SHH),
notch, wingless-type MMTV integration site family member
(WNT), maternal embryonic leucine-zipper kinase (MELK),
andBlymphomaMo-MLVinsertionregion1(BMI1),which
are associated with self-renewal and neoplastic proliferation.
These altered pathways may represent possible targets for
GSCs.
4.1. PI3K/Akt/mTOR Pathway Including the PTEN Pathway.
PTEN suppresses Akt phosphorylation by reversing PI3K-
driven phosphorylation, resulting in the inhibition of PIP3
signalingandthesuppressionofcellproliferation.The PTEN
gene is mutated in 15–40% of primary GBM cases. PTEN
deletionswithretinoblastoma-associatedprotein(pRb)inac-
tivation or ABCG2 transporter activation accelerate the
formation of aggressive high-grade tumors and GSC-like
neurosphere formation capacity in a transgenic mouse
model of glioma [71–75]. Although PTEN is one of the
most remarkable targets involved in GSC activity, its status
in GSCs has yet to be elucidated. The dysfunction of PTEN
leads to the activation of the PI3K/Akt/mTOR pathway.
Therefore, therapy targeting the PI3K/Akt/mTOR pathway
describedabovemaybealsoeﬀectiveagainstGSCsexhibiting
PTEN dysfunction. Thus, these results suggest the potential
of eﬃciency of such therapies for GSCs.
4.2. SHH Pathway. SHH is a secreted protein critical for
pattern formation in the central nervous system. SHH ligand
binding to its receptors, patched homolog (PTCH) and
smoothened homolog (SMO), leads to the activation of glio-
tactin (GLI) transcription factors that are translocated into
the nuclease to regulate various cellular activities, including
the maintenance of cell stemness, survival, and proliferation.
Altaba et al. demonstrate that SHH signaling regulates
the expression of stemness genes such as Nanog homeobox
(NANOG), SRY-box containing gene 2 (SOX2), and octamer-
binding protein 4 (OCT4). In addition, they demonstrate
that SHH-GLI signaling is required not only for sustained
glioma growth and survival but also for GSC survival and
proliferation [76]. Considering these reports, the inhibition
of the SHH signaling pathway may be a target of therapy.
The novel SMO inhibitor, vismodegib (GDC-0449), exhibits
antitumor activity in a mouse model of medulloblastoma
and primary human tumor cell xenograft models including
colorectalcancerandpancreaticcarcinoma.AphaseIclinical
trial was initiated on the basis of these preclinical tests;
the results demonstrate that vismodegib is generally well
tolerated with an acceptable safety proﬁle in refractory8 Neurology Research International
locally advanced metastatic solid tumors, including basal
cell carcinoma and medulloblastomas [77]. Therefore, the
SHH signaling pathway may be a potential target for therapy
against GSCs.
4.3. Notch Pathway. The Notch pathway is initiated by the
binding of transmembrane ligands on one cell to the notch
receptors on an adjacent cell. This binding causes the γ-
secretase-mediated proteolytic release of the Notch intracel-
lular domain (NICD). Released NICD translocates into the
nucleus and then turns CSL (a transcriptional factor) from a
repressor to an activator, causing various eﬀects [78]. Notch
controls the speciﬁcation, proliferation, and survival of
nonneoplastic neural precursors and is aberrantly activated
in embryonal brain tumors, suggesting a molecular link
between neural stem cells and medulloblastomas. Previously,
Sullenger et al. demonstrated that GSCs promote radiore-
sistance compared with GBM tumor bulk because GSCs
preferentially activate the DNA damage-response pathway.
Notch signaling plays an important role in this DNA damage
response pathway via the activation of the PI3K/Akt pathway
and the pro-survival protein, Mcl-1. Notch pathway inhi-
bition using γ-secretase inhibitors (GSIs; MK0752) impairs
cellgrowth,clonogenicsurvival,andtumorformationability
and sensitizes GSCs to radiation at clinically relevant doses
[79, 80].
4.4. Wingless-Type MMTV Integration Site Family Member
(Wnt) Pathway. Wnt signals are divided into 2 diﬀerent
pathways: the canonical, or WNT/β-catenin pathway is
involved in cell fate determination and the noncanonical
pathway is involved in the control of cell movement and
tissue polarity [35]. Following the binding of Wnt protein
to a receptor complex comprising Frizzleds/low-density
lipoprotein receptor-related protein (Fz/LRP), cytoplasmic
disheveled (Dvl) is phosphorylated. The phosphorylation
of Dvl inhibits the activity of glycogen synthase kinase-3β
(GSK-3β), elevating nonphosphorylated β-catenin levels in
the cytoplasm. β-Catenin translocates into the nucleus and
forms a complex with members of the T-cell transcription
factor (TCF)/lymphoid enhancer-binding factor (LEF) fam-
ily of transcription factors [81]. Epigenetic silencing and
loss-of-function mutations of negative regulators of WNT
signaling are observed in a variety of human cancers. It is
suggested that Wnt signaling is also involved in the regu-
lation of cancer stem cells because of the many similarities
in the pathways that regulate normal and cancer stem cells.
Therefore, the inhibition of Wnt signaling may disrupt
the maintenance of the stemness of GSCs. Although they
include preclinical agents, several agents inhibiting the Wnt
pathway are suggested for potential clinical use in a review
by Takahashi-Yanaga and Kahn [82]. Of these agents, those
that are used clinically are NSAIDs such as aspirin, sulindac,
and celecoxib; celecoxib is the only NSAID approved by the
Food and Drug Administration (FDA) for the treatment of
familial adenomatous polyposis. The inhibition of the Wnt
pathway by celecoxib has been shown by its ability to induce
the degradation of TCF.
These various pathways altered in GBM or in the pres-
ence of GSCs with altered signaling pathways may induce
resistance to conventional therapy. In addition, in other can-
cers, several studies suggest the eﬃciency of various small-
molecule inhibitors. Although several clinical trials of these
inhibitors in GBM have been performed, almost all failed to
demonstrate the eﬃciency of these inhibitors compared with
conventional therapy. We expect that combinations of these
agents may overcome resistance to treatment or change the
deﬁnition of patients who should be treated by each agent to
induce a more favorable response.
5.Bypassingthe Blood-Brain Barrier
The blood-brain barrier blocks most molecules that are
larger than ∼500Da. Many drugs are denied access to the
very regions where they would be eﬀective, thus limiting
the clinical application of most anticancer drugs for treating
brain tumors. Each anticancer agent showed various perme-
ability for BBB, although the relationship of its permeability
totherapeuticeﬃcacyisnotclear[83].Althoughseverallocal
therapies are attempted to overcome this BBB or “blood-
tumor barrier,” local therapies should be more developed to
deliver therapeutic agents in more distant locations due to
highly inﬁltrative nature of high-grade gliomas.
5.1. Gliadel (Carmustine, BCNU) Wafers. A meta-analysis
combining the results of the randomized phase III trial
published by Westphal et al. [84] and an earlier randomized
phase III study by Valtonen et al. [85] demonstrates that the
subgroup of GBM treatments with BCNU wafers increases
mean survival to 13.1 months compared with 10.9 months
for placebo patients (P = 0.03). The results of the 2 trials
led the FDA to approve Gliadel for the treatment of newly
diagnosed GBM in 2003. A combination of local BCNU
wafer treatment and concomitant radiochemotherapy with
TMZisattractivenotonlybecauseitmaysigniﬁcantlyreduce
the toxicity of a systemic combination of BCNU and TMZ as
describedabovebutalsobecauseitmaytakeadvantageofthe
sensitizingeﬀectofTMZandBCNUontheirrespectiveresis-
tance by MGMT [86]. However, several complications are
associated with the implantation of BCNU wafers, including
cerebral edema, healing abnormalities, cerebral spinal ﬂuid
leaks, intracranial infections, seizures, hydrocephalus, and
cyst formation. The rates for these adverse events were well
established in 2 randomized phase III trials that compared
BCNU wafers with placebo ones. Gliadel wafer implantation
may add to the toxicity of concomitant radiochemotherapy
with systemic TMZ. Therefore, the combined approach
requires special attention [87].
5.2. Convection-Enhanced Delivery. A direct intracerebral
approach called convection-enhanced delivery (CED) may
be used as a strategy to address these issues [88–90]. CED
employs positive pressure that generates a local pressure
gradienttodistributeagentsintheextracellularspace.Unlike
diﬀusion delivery, CED is not signiﬁcantly aﬀected by the
concentration,molecularweight,orparticlesizeoftheagent.
Furthermore, CED ensures high concentrations and theNeurology Research International 9
homogenousdistributionofadrugthroughoutagiventarget
tissue.
5.3. CED of IL13-PE38QQR (Cintredekin Besudotox) for
Recurrent GBM: The PRECISE Study. Interleukin (IL)-13
is a cytokine derived from type 2 T-helper cells and can
bind to 2 receptor chains: IL-13Rα1 and IL-13Rα2; IL-13
has low aﬃnity for the IL-13Rα1 chain and high aﬃnity
for the IL-4Rα chain. It forms a receptor complex with
the IL-4Rα chain, which is involved in IL-13-induced signal
transduction via either Janus kinase/signal transducer and
activator of transcription (JAK-STAT) or PI3K [91]. The IL-
13Rα2chainbindstoIL-13withhighaﬃnityandinternalizes
it after ligand binding without the involvement of other
chains.
IL-13R is overexpressed in a majority of glioma cell
lines and resected GBM specimens [92]. A chimeric fusion
protein composed of human IL-13 and mutated forms of
Pseudomonas aeruginosa exotoxin A (PE38QQR) has been
developed and shown to aﬀect the speciﬁc cytotoxicity of
glioma cell lines [92, 93].
IL-13-PE is reported to be more active against glioma cell
lines than IL-4-targeted toxins in vitro [93]. In a phase I trial,
51 patients with GBM were administered IL-13-PE38QQR
via CED [94]. A phase III study was conducted to compare
the eﬃcacy of IL-13-PE to that of Gliadel wafers in patients
with malignant gliomas [93]. PFS was longer (17.7 versus
11.4weeks)inpatientstreatedwithIL-13-PEthaninpatients
treated with Gliadel wafers; however, there was no signiﬁcant
diﬀerence in the median survival time between the 2
groups.
Overall, IL-13-based toxins can be potentially used in
adjuvant therapy for malignant gliomas, but their use re-
quires further clinical studies.
5.4. CED of TGF-β Antisense: The SAPPHIRE Study. Trans-
forming growth factor-beta (TGF-β) is a multifunctional
regulatory polypeptide belonging to a ligand superfamily
that includes the TGF-βs, activins, and bone morphogenetic
proteins (BMPs). TGF-β controls many aspects of cellular
function including proliferation, diﬀerentiation, migration,
apoptosis, adhesion, angiogenesis, immune surveillance, and
survival. Three TGF-β isoforms have been found: TGF-
β1, TGF-β2, and TGF-β3. The TGF-β2 isoform is speciﬁ-
cally overexpressed in malignant gliomas. Increased TGF-
β2 levels are associated with advanced disease stage and
cause immunodeﬁciencies in patients with gliomas [95].
TGF-β2 not only inhibits lymphocyte proliferation but
also has multiple eﬀects on the immune system. These
eﬀectsincludeinhibitionofimmunecellactivation,blockage
of antitumor activity, shift in cytokine balance toward
immunosuppression, and inhibition of antigen presentation.
Thus, the targeted inhibition of TGF-β2 should have an
antitumor eﬀect and allow an immune-mediated response.
Several approaches to block TGF-β function are currently
being studied including the use of monoclonal antibodies
against TGF-β, recombinant fusion proteins containing the
ectodomains of TGF-β receptor (TβR)II and TβRIII to
prevent the binding of TGF-β ligands, ATP competitive
inhibitors at the ATP-binding site of TβRI kinase, and
antisense oligonucleotides speciﬁc for TGF-β2[ 96–101].
Trabedersen (AP-12009) is a synthetic antisense oligo-
deoxynucleotide designed to block TGF-β2p r o d u c t i o n
[102]. In a randomized controlled phase IIb trial involving
patients with brain tumors, the survival rates of patients
for whom trabedersen was intratumorally administered were
higher than those of patients receiving standard chemother-
apy [103]. An international clinical phase III trial is currently
recruiting patients with recurrent or refractory anaplastic
astrocytoma. A randomized controlled dose-ﬁnding phase
IIb study evaluated the eﬃcacy and safety in 145 patients
with recurrent or refractory high-grade gliomas [104]. The
patients were randomly assigned to receive 10 or 80μM
trabedersen or standard chemotherapy. The primary end
point was 6-month tumor control rate. Although this study
failed to meet the primary end point, it could be due to
thepseudoprogressionthatoccurswithimmunetherapies.A
prescribed anaplastic astrocytoma subgroup analysis found
a signiﬁcant beneﬁt for 10μM trabedersen with respect
to the 14-month tumor control rate. The 2-year survival
rate for 10μM trabedersen tended to be superior to those
of the other treatments. An international clinical phase
III trial is currently recruiting patients with recurrent or
refractory anaplastic astrocytomas with end points of 14-
month progression rate and 2-year survival rate.
6.FuturePerspectives
The Cancer Genome Atlas (TCGA) is a project that catalogs
genomic abnormalities that are involved in the develop-
ment of cancer [105, 106]. TCGA published the results
of its ﬁrst study in a large GBM cohort consisting of
206 patient samples. Techniques that are currently used
for detection of abnormalities include gene-expression pro-
ﬁling, copy-number variation proﬁling, single-nucleotide
polymorphism (SNP) genotyping, genome-wide methyla-
tion proﬁling [107], microRNA proﬁling [108], and exon
sequencing. Since the publication of the ﬁrst paper, several
analysis groups within the TCGA Network have presented
the results of highly detailed analyses of GBM. Verhaak et
al. [109] recently subclassiﬁed GBM into proneural, neural,
classical, and mesenchymal subtypes by integrating multi-
dimensional data on gene expression, somatic mutations,
and DNA copy number. The major features of the Proneural
class are focal ampliﬁcation of PDFRA, IDH1 mutation,
and TP53 mutation and/or loss of heterozygosity. Moreover,
the group showed high expression of genes associated with
oligodendrocyte development, such as PDGFRA, NKX2-2,
and OLIG2. The Neural subtype is characterized by the
expressionofneuronmarkerssuchasNEFL,GABRA1,SYT1,
and SLC12A5. The Classical subtype features high EGFR
expression associated with chromosome 7 ampliﬁcation and
low expression of p16INK4A and p14ARF, resulting from
focal 9p21.3 homozygous deletion. Neural stem cell markers
such as nestin, as well as components of the Notch and
Sonic hedgehog signaling pathways, are highly expressed in
theClassicaltype.TheMesenchymalsubtypeischaracterized
by focal hemizygous deletions at 17q11.2 that contains NF110 Neurology Research International
and high expression of YKL-40 (CHI3L1), MET, CD44,a n d
MERTK. Genes in the tumor necrosis factor superfamily
pathway and NF-kappaB pathway, such as TRADD, RELB,
and TNFRSF1A, are highly expressed in this subtype.
The classiﬁcation of GBM may lead to establishment of
personalized therapies for groups of patients with GBM.
However, the results of clinical studies of EGFR and PDGFR
inhibitors as monotherapy are disappointing thus far. While
research and development of more promising molecular-
targeted agents are needed in the laboratory, molecular-
targetedagentsarelikelytohavesynergisticantitumoreﬀects
in combination. On the other hand, strategies of how to
evaluate better ways to design early phase clinical trials, to
choose better endopoints should avoid trials that will not
provide helpful answers. The discrepancy between PFS and
OS as endpoints are still controversial; also the question
when and how to integrate new therapies into the backbone
of standard therapy still remains.
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